Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

Do patients with CKD benefit from lipid-lowering therapy?

Nature Reviews Nephrology volume 8, pages 684–685 (2012)Cite this article

The appropriate use of lipid-lowering therapy in patients with chronic kidney disease (CKD) remains unclear. The results of two recent, robust systematic reviews and meta-analyses of lipid-lowering therapy in patients with CKD seem to support the use of lipid-lowering therapy. But is the story more complex?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jardine, A. G., Gaston, R. S., Fellstrom, B. C. & Holdaas, H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378, 1419–1427 (2011).

    Article  Google Scholar 

  2. Upadhyay, A. et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 251–262 (2012).

    Article  Google Scholar 

  3. Palmer, S. C. et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 263–275 (2012).

    Article  Google Scholar 

  4. Holdaas, H. et al. Rosuvastatin in diabetic hemodialysis patients. J. Am. Soc. Nephrol. 22, 1335–1341 (2011).

    Article  CAS  Google Scholar 

  5. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181–2192 (2011).

    Article  CAS  Google Scholar 

  6. Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).

    Article  CAS  Google Scholar 

  7. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).

    Article  CAS  Google Scholar 

  8. Marz, W. et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 6, 1316–1325 (2011).

    Article  Google Scholar 

  9. Holdaas, H. et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361, 2024–2031 (2003).

    Article  CAS  Google Scholar 

  10. Holdaas, H. et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am. J. Transplant. 5, 2929–2936 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Sognsvannsveien 20, Oslo, 0027, Norway

    Hallvard Holdaas

  2. British Heart Foundation Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA, UK

    Alan Jardine

Authors
  1. Hallvard Holdaas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Jardine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hallvard Holdaas.

Ethics declarations

Competing interests

H. Holdaas declares associations with the following companies: AstraZeneca (speakers' bureau, grant/research support), Merck/Schering Plough (grant/research support), Novartis (speakers' bureau). A. Jardine declares associations with the following companies: AstraZeneca (speakers' bureau, grant/research support), Novartis (grant/research support).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holdaas, H., Jardine, A. Do patients with CKD benefit from lipid-lowering therapy?. Nat Rev Nephrol 8, 684–685 (2012). https://doi.org/10.1038/nrneph.2012.240

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2012.240

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing